💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Daclatasvir

CHEMBL2023898 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
738.9 g/mol
LogP
5.1
Phase
4

An NS5A inhibitor that disrupts the hepatitis C virus replication complex by targeting the NS5A protein, used in combination with other direct-acting antivirals to treat chronic hepatitis C. It achieves very high cure rates when used in appropriate combination regimens.

분자량

738.9000 g/mol

LogP

5.10

TPSA

175.00 Ų

리핀스키 5의 법칙

불통과

치료 영역

HIV/AIDS Hepatitis C

작용 기전

Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C

                

                

                
                

                    
InChI

                    
InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C40H50N8O6

                    

                    
                    

                        
HBD / HBA

                        
4 / 8

                    

                    
                    

                        
회전 가능 결합

                        
13

                    

                    
                    
                    

                        
무거운 원자

                        
54

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
An NS5A inhibitor that disrupts the hepatitis C virus replication complex by targeting the NS5A protein, used in combination with other direct-acting antivirals to treat chronic hepatitis C. It achieves very high cure rates when used in appropriate combination regimens.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Daclatasvir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2023898.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 25154714.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.